Aim To analyze the 3-year outcomes of lower body mass
index (BMI) (<35 kg/m2) adjustable gastric band (AGB) recipients
across multiple sites in the French health insurance
system.
Methods From prospectively collected data on a cohort
of 517 morbidly obese Swedish Adjustable Gastric
Band® (SAGB) patients (Clinical Trials Web database,
#NCT01183975), a retrospective analysis of a subgroup of
29 low-BMI patients was conducted. Patients had a severe
obesity-related comorbidity, had undergone a prior bariatric
procedure requiring reintervention, or had a maximum
adult BMI≥40. Safety (mortality, adverse events) and effectiveness
(BMI change, excess weight loss [EWL, %], total
body weight loss [%TBWL], quality of life [QoL], and comorbidities)
were evaluated.
Results Multiple surgical teams/sites enrolled patients
and performed SAGB procedures between September 2,
2007 and April 30, 2008. Of 29 low-BMI patients (mean age,
41.3 ± 10.3 years), 89.7% were female, and obesity duration
was 13.6 ± 7.3 years. Mean BMI was 31.5 ± 3.7; there were
37 comorbidities in 15/29 patients. At 3-year follow-up,
BMI was 29.4 ± 4.9 (mean change, -2.3 ± 6.2; P = 0.069); total
cohort EWL, 7.3 ± 74.8%; TBWL, 6.2 ± 18.8%; BMI≥30 to
<35 EWL, 38.8 ± 48.0%; there were 7 comorbidities in 15/29
patients (P < 0.031). There were 20 adverse events in 13 patients
(44.8%); SAGBs were retained in 25/29 (86.2%) at 3
years.
Conclusions In a retrospective analysis of a subgroup
of BMI<35 kg/m2 patients, some following a prior bariatric
procedure, SAGB was found to be safe and effective at
3-year follow-up
